UltraSensitive Residual Leukemia Detection with Patient-Specific Duplex Sequencing

Dr. Jesse Salk reviews using Duplex Sequencing to measure ultra-rare mutations from carcinogens, aging, and the earliest stages of cancer.

View the Webinar

Presented by

Covered in this Webinar

Goals of TwinStrand Biosciences

Duplex Sequencing technology versus standard sequencing

Capturing ultra-rare mutations from sequencing data

Jesse Salk, MD, PhD, is the CEO and CSO of TwinStrand Biosciences. He explains the challenges of finding a genetic needle in a haystack and shares how Twist's technology and target enrichment solutions help him achieve the otherwise "crazy" results he's seeking from patient samples using duplex sequencing.

Share your details to Watch the Webinar

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

UltraSensitive Residual Leukemia Detection with Patient-Specific Duplex Sequencing

Related Resources

Highly Sensitive Methylation Detection Using Enzymatic Methyl-seq and Twist Target Enrichment

Twist Targeted Methylation Sequencing Protocol

NGS Methylation Detection System